Evidence map›Paper›PMID 39499047›Full record

ArticleCancer medicine2024

Transarterial Infusion Chemotherapy and Embolization for Patients With Unresectable Advanced Cancer of Stomach or Gastroesophageal Junction: A Retrospective Study.

Lingqiang Min, Zheng Liu, Bo Zhou, Peng Zhou, Rongkui Luo, Yuqin Ding, Yuehong Cui, Zhongyi Shi, Yuan Gu, Yihong Sun and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lingqiang MinDepartment of Emergency Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Zheng LiuShanghai Medical College, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0001-9105-2268
Bo ZhouDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Peng ZhouDepartment of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Rongkui LuoDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuqin DingDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuehong CuiDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhongyi ShiDepartment of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan GuDepartment of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yihong SunDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhaoqing TangDepartment of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Xuefei WangDepartment of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe feasibility of transarterial infusion chemotherapy and embolization (TAICE) in the treatment of advanced gastric cancer remains unclear. This study explored the value of TAICE in patients with unresectable locally advanced or metastatic cancer of stomach or gastroesophageal junction (GEJ).

methodsPatients with unresectable gastric cancer who received TAICE for tumor hemorrhage cessation were enrolled in this retrospective study. TAICE was performed using the Seldinger method. The tumor feeding artery was selected for infusion chemotherapy and then was embolized by microspheres or gelatin sponge. Patients involved in this study received one to four cycles TAICE with one to three drugs in the regimen. The possibility of surgery was evaluated after TAICE. Objective response rate (ORR), disease control rate (DCR), R0 resection rate, pathological complete remission (pCR) rate, major pathological remission (MPR) rate, progression-free survival (PFS), overall survival (OS), and safety were analyzed.

resultsBetween January 2015 and December 2020, a total of 27 patients received a median of 2 (range, 1-4) cycles of TAICE. ORR and DCR were 33.3% and 74.0%, respectively. Eighteen patients received surgery, and 15 of them underwent gastrectomy and D2 lymph node dissection, with an R0 resection rate of 83.3% (15/18). Four (26.7%, 4/15) patients achieved MPR, but none achieved pCR. The median PFS was 19.8 months (95%CI, 12.1-40.0), and the median OS was 36.1 months (95%CI, 21.0-not reached). Patients with gastrectomy had significantly longer PFS (40.0 vs. 9.5 months, p < 0.0001) and OS (not reached vs. 16.6 months, p < 0.0001) than those without gastrectomy. All the TAICE-related adverse events were manageable, with the most common being fatigue (100%), nausea (63.0%), and vomiting (55.6%). No severe surgical complications occurred.

conclusionTAICE was well-tolerated and could be a potential therapy to provide opportunity of surgery for patients with unresectable advanced gastric or GEJ cancer.

Indexed as

Esophagogastric JunctionInfusions, Intra-ArterialStomach NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsEmbolization, TherapeuticFeasibility StudiesFemaleGastrectomyHumansMaleMiddle AgedRetrospective StudiesTreatment Outcomeretrospective studytransarterial infusion chemotherapy and embolizationunresectable gastric cancer

Identifiers

PMID39499047
PMCPMC11536461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.